- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00559884
A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects
May 31, 2012 updated by: GlaxoSmithKline
An Open-label, Randomized, Single Dose, Crossover Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Modified Release Formulations of GSK189075 in Healthy Volunteers
The purpose of this research study is to look at concentrations of GSK189075 in blood when different long and short acting forms of the drug are taken by mouth.
The results will help to decide whether a long-acting form of GSK189075 can be made.
The effects of the drug on the body and safety will also be studied.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43212
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Are a healthy, non-smoking adult, 18 to 55 years old.
- Are not overly thin or overly heavy for your height.
- Are a female who is unable to have children, or is willing to use birth control throughout the study.
- Are willing and able to follow all study-related instructions provided by the site staff. - Are willing to provide signed consent.
Exclusion Criteria:
- Are a pregnant or a nursing female.
- Have a past or current disease such as heart, liver, kidney, blood, brain, or other disease.
- Have had certain infections within 4 weeks before the expected the first dose of study drug.
- Have HIV or hepatitis, or have alcohol in your system at the screening visit.
- Have a history of alcohol abuse.
- Have been in another research study in the last month or have taken certain medications in the 2 weeks before study drug would be taken.
- Have laboratory tests that are outside the normal range.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood samples:
Time Frame: collected over 24-hour period after each different form of GSK189075 given to measure amount of drug in blood
|
collected over 24-hour period after each different form of GSK189075 given to measure amount of drug in blood
|
Urine:
Time Frame: collected over 24-hour period after dosing with each form to measure amount of urine produced & amount of sugar in urine
|
collected over 24-hour period after dosing with each form to measure amount of urine produced & amount of sugar in urine
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events:
Time Frame: all visits after Day -1
|
all visits after Day -1
|
blood pressure & heart rate:
Time Frame: screening,Day -1 - Day 1,follow-up visit
|
screening,Day -1 - Day 1,follow-up visit
|
ECGs:
Time Frame: screening,pre-dose, Day 1
|
screening,pre-dose, Day 1
|
lab tests:
Time Frame: screening, Day -1 - Day 1,follow-up
|
screening, Day -1 - Day 1,follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Study Registration Dates
First Submitted
November 14, 2007
First Submitted That Met QC Criteria
November 14, 2007
First Posted (Estimate)
November 16, 2007
Study Record Updates
Last Update Posted (Estimate)
June 4, 2012
Last Update Submitted That Met QC Criteria
May 31, 2012
Last Verified
February 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KGW111057
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
HighTide Biopharma Pty LtdRecruitingT2DM (Type 2 Diabetes Mellitus)China
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
Clinical Trials on GSK189075 (Modified and immediate release formulations)
-
Heptares Therapeutics LimitedQuotient ClinicalCompletedAlzheimer's DiseaseUnited Kingdom
-
GlaxoSmithKlineQuotient ClinicalCompletedAutoimmune DiseasesUnited Kingdom
-
GlaxoSmithKlineQuotient SciencesCompletedAutoimmune DiseasesUnited Kingdom
-
PfizerViiV HealthcareCompleted
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States
-
KalVista Pharmaceuticals, Ltd.Completed
-
GlaxoSmithKlineCompletedMultiple Sclerosis, Relapsing-RemittingAustralia
-
AmgenCompletedHealthy VolunteersUnited States
-
PfizerCompletedHealthy ParticipantsBelgium